Details for Patent: 8,598,186
✉ Email this page to a colleague
Which drugs does patent 8,598,186 protect, and when does it expire?
Patent 8,598,186 protects COSELA and is included in one NDA.
This patent has fifty-nine patent family members in twenty-four countries.
Summary for Patent: 8,598,186
| Title: | CDK inhibitors |
| Abstract: | Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors. |
| Inventor(s): | Tavares; Francis X. (Durham, NC), Strum; Jay C. (Hillsborough, NC) |
| Assignee: | G1 Therapeutics, Inc. (Chapel Hill, NC) |
| Application Number: | 13/869,520 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 8,598,186
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacosmos | COSELA | trilaciclib dihydrochloride | POWDER;INTRAVENOUS | 214200-001 | Feb 12, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,598,186
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011323739 | ⤷ Sign Up | |||
| Australia | 2016204879 | ⤷ Sign Up | |||
| Australia | 2018202991 | ⤷ Sign Up | |||
| Australia | 2020203035 | ⤷ Sign Up | |||
| Australia | 2020203037 | ⤷ Sign Up | |||
| Brazil | 112013010018 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
